CliffBio
small molecule

KETOCONAZOLE

KETOCONAZOLE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameKETOCONAZOLE
Active ingredientKETOCONAZOLE
Strength200MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 1999
Marketing statusRX

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.